

**IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE**

Serial. No. : 10/566,826
Applicants : Akio KIMURA et al.
Filed : January 31, 2006
For : PROSTAGLANDIN-
CONTAINING PRODUCT
Art Unit : 1618
Examiner : Jake Minh VU
Docket No. : 06067/HG
Confirm No. : 8012
Customer No. : 01933

This paper is being submitted
via EFS-Web on

October 20, 2011

In the event that this Paper
is late filed, and the
necessary petition for
extension of time is
not filed concurrently
herewith, please consider
this as a Petition for the
requisite extension of time,
and to the extent not already
paid, authorization to charge
the extension fee to Account
No. 06-1378. In addition,
authorization is hereby given
to charge any fees for which
payment has not been submitted,
or to credit any overpayments,
to Account No. 06-1378.

**INFORMATION DISCLOSURE STATEMENT AND STATEMENT UNDER 37
CFR 1.97(e)(2)**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SIR :

The enclosed IDS Form identifies documents (Baker et al. and CAS (entry RN9010-29-1, 2011)) that were cited in copending related application Serial No. 11/792,637. A copy of the non-patent document identified on the enclosed IDS form is enclosed.

The following prior art rejection was set forth in the August 9, 2011 Office Action in copending related application Serial. No. 11/792,637:

“Claims 1 and 9 are rejected under 35 U.S.C. 103(a) as being unpatentable over Baker et al. (US Pub. 2005/0049311) in view of Fetz et al. (WO2002/51452) and Kis et al. (WO0073156, provided by Applicant on the IDS dated 10/18/2010), as evidenced by CAS (entry for RN 9010-79-1, 2011).”

STATEMENT UNDER 37 CFR 1.97(e)(2)

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the information disclosure statement.

The USPTO fee of \$180 is being paid by credit card herewith.

It is respectfully requested that an initialed copy of the enclosed IDS Form be returned to the undersigned to indicate that all the documents listed therein were considered and made of record.

Holtz, Holtz, Goodman
& Chick PC
220 Fifth Ave., 16th Floor
New York, NY 10001-7708
Tel. No.: (212) 319-4900
Fax No.: (212) 319-5101

Respectfully submitted,


Richard S. Barth
Richard S. Barth
REG. NO. 28,180

E-Mail Address: rbarth@hhpatent.com
RSB/ean

Encs.